Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis

Prostate

Volumn 73, Issue 10, 2013, Pages 1090-1102

  Boutin, Benoît ^a   Tajeddine, Nicolas ^a   Vandersmissen, Patrick ^a   Zanou, Nadège ^a   Van Schoor, Monique ^a   Mondin, Ludivine ^a   Courtoy, Pierre J ^a   Tombal, Bertrand ^a,b   Gailly, Philippe ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

androgen; apoptosis; autophagy; chloroquine; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; AUTOPHAGY PROTEIN 5; BECLIN 1; BICALUTAMIDE; CHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN; SMALL INTERFERING RNA;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BINDING COMPETITION; CANCER CELL CULTURE; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL ASSAY; CELL CYCLE G1 PHASE; CELL MEMBRANE PERMEABILITY; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN DEPLETION; QUANTITATIVE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CHLOROQUINE; HUMANS; MALE; NITRILES; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TOR SERINE-THREONINE KINASES; TOSYL COMPOUNDS;

EID: 84878453629     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22658     Document Type: Article

References (28)

1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC,. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28 (3): 555-565.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351 (15): 1513-1520.
3. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26 (2): 242-245.
4. Knudsen KE, Scher HI,. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15 (15): 4792-4798.
5. Devlin HL, Mudryj M,. Progression of prostate cancer: Multiple pathways to androgen independence. Cancer Lett 2009; 274 (2): 177-186.
6. Shen MM, Abate-Shen C,. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res 2007; 67 (14): 6535-6538.
7. Sarker D, Reid AH, Yap TA, de Bono JS,. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15 (15): 4799-4805.
8. Galluzzi L, Vicencio JM, Kepp O, Tasdemir E, Maiuri MC, Kroemer G,. To die or not to die: That is the autophagic question. Curr Mol Med 2008; 8 (2): 78-91.
9. Cuervo AM,. Autophagy many paths to the same end. Mol Cell Biochem 2004; 263 (1-2): 55-72.
10. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132(1):27-42.
11. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo- Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Banhegyi G, Bartholomew CR, Bassham DC, Bast RC Jr, Batoko H, Bay BH, Beau I, Bechet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012;8(4):445-544
12. Galluzzi L, Morselli E, Vicencio JM, Kepp O, Joza N, Tajeddine N, Kroemer G,. Life, death and burial: Multifaceted impact of autophagy. Biochem Soc Trans 2008; 36 (Pt 5): 786-790.
13. Tsujimoto Y, Shimizu S,. Another way to die: Autophagic programmed cell death. Cell Death Differ 2005; 12 (Suppl 2): 1528-1534.
14. Bursch W, Ellinger A, Gerner C, Frohwein U, Schulte-Hermann R,. Programmed cell death (PCD). Apoptosis, autophagic PCD, or others ? Ann N Y Acad Sci 2000; 926: 1-12.
15. Glick D, Barth S, Macleod KF,. Autophagy cellular and molecular mechanisms. J Pathol 2010; 221 (1): 3-12.
16. Kroemer G, Levine B,. Autophagic cell death: The story of a misnomer. Nat Rev Mol Cell Biol 2008; 9 (12): 1004-1010.
17. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E,. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173 (2): 534-540.
18. Mizushima N, Yoshimori T,. How to interpret LC3 immunoblotting. Autophagy 2007; 3 (6): 542-545.
19. Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G, Morel L,. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 2004; 279 (15): 14579-14586.
20. Ni HM, Bockus A, Wozniak AL, Jones K, Weinman S, Yin XM, Ding WX,. Dissecting the dynamic turnover of GFP-LC3 in the autolysosome. Autophagy 2011; 7 (2): 188-204.
21. Li M, Jiang X, Liu D, Na Y, Gao GF, Xi Z,. Autophagy protects LNCaP cells under androgen deprivation conditions. Autophagy 2008; 4 (1): 54-60.
22. Bennett HL, Fleming JT, O'Prey J, Ryan KM, Leung HY,. Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis 2010; 1: e72.
23. Chhipa RR, Wu Y, Ip C,. AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. Cell Signal 2011; 23 (9): 1466-1472.
24. Xu Y, Chen SY, Ross KN, Balk SP,. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res 2006; 66 (15): 7783-7792.
25. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ,. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 2003; 278 (44): 42992-43000.
26. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A,. Life and death partners: Apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16 (7): 966-975.
27. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G,. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8 (9): 741-752.
28. Livesey KM, Tang D, Zeh HJ, Lotze MT,. Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs 2009; 10 (12): 1269-1279.